摘要
趋化因子受体是HIV进入靶细胞的必要协同受体,其识别是了解HIV病毒感染发病机制的重要突破。除了其通过结合协同受体阻断病毒进入的作用外,趋化因子在艾滋病发病机制中还有着其它功能。事实上,趋化因子可以抑制或增强艾滋病毒的复制从而影响病毒的生命周期。根据对艾滋病毒复制和传播的消极与积极不同影响,趋化因子对HIV 发病机制也有着不同的作用。CCL2 是一种特殊的趋化因子,其主要加强病毒复制和发病机制。无论是HIV感染本身还是暴露于病毒中都可诱导趋化因子及其受体CCR2的表达、并且能发现HIV感染者中CCL2/CCR2表达水平较高。CCL2/CCR2轴与高水平免疫激活和炎症紧密相关。即使对于正在接受抗逆转录病毒治疗的患者,炎症也是HIV 感染的标志之一。此外,CCL2对HIV复制的直接影响越来越明显。CCL2 /CCR2驱动效应的调节对HIV疾病过程有着重要影响。基于CCL2/CCR2轴的抑制作用,本文讨论了CCL2/CCR2和HIV以及新兴治疗方法之间复杂关系。
关键词: CCL2 CCR2艾滋病毒,炎症,发病机制,治疗。
图形摘要
Current Drug Targets
Title:The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Volume: 17 Issue: 1
Author(s): Daniela Angela Covino, Michela Sabbatucci and Laura Fantuzzi
Affiliation:
关键词: CCL2 CCR2艾滋病毒,炎症,发病机制,治疗。
摘要: The identification of chemokine receptors as necessary co-receptors for HIV entry into target cells represented a breakthrough in the understanding of the pathogenesis of this viral infection. Since this initial discovery, it was unraveled that chemokines, in addition to their role in blocking viral entry by binding to co-receptors, have other functions in HIV pathogenesis. Indeed, chemokines can either inhibit or enhance HIV replication, and these effects may involve both entry and post-entry events of the viral life cycle. Depending on the balance of their negative versus positive effects on HIV replication and spreading, chemokines contribute to different outcomes of HIV pathogenesis. CCL2 is unique among the chemokines in that mostly enhancing effects on viral replication and pathogenesis have been reported. Either HIV infection itself or exposure to viral products can induce the expression of this chemokine and of its receptor CCR2, and high levels of CCL2/CCR2 are indeed found in HIV-infected subjects. The CCL2/CCR2 axis is tightly linked to the high level of immune activation and inflammation that is the hallmark of HIV infection even in patients undergoing antiretroviral therapy. In addition, more direct effects of CCL2 on HIV replication are becoming apparent. Thus, modulation of CCL2/CCR2-driven effects may have significant impact on HIV disease progression. In this review, we will discuss the complex interaction between CCL2/CCR2 and HIV and the emerging therapeutic approaches based on the inhibition of this axis.
Export Options
About this article
Cite this article as:
Daniela Angela Covino, Michela Sabbatucci and Laura Fantuzzi , The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?, Current Drug Targets 2016; 17 (1) . https://dx.doi.org/10.2174/138945011701151217110917
DOI https://dx.doi.org/10.2174/138945011701151217110917 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Cellular Targets for Anticancer Strategies
Current Drug Targets Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Double Layered Hydroxides as Potential Anti-Cancer Drug Delivery Agents
Mini-Reviews in Medicinal Chemistry Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Nanoparticles in Cancer
Current Radiopharmaceuticals Design and Development of Glutathione Conjugated Poly (d, l) lactide Nanocarriers for Delivery of Hydrophilic Fluorescent Marker across Blood Brain Barrier
Current Nanoscience Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
Current Cancer Drug Targets Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design